Compare TRST & GERN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | TRST | GERN |
|---|---|---|
| Founded | 1902 | 1990 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 699.3M | 753.3M |
| IPO Year | N/A | 1996 |
| Metric | TRST | GERN |
|---|---|---|
| Price | $42.41 | $1.31 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $3.00 |
| AVG Volume (30 Days) | 102.4K | ★ 7.7M |
| Earning Date | 01-20-2026 | 11-05-2025 |
| Dividend Yield | ★ 3.58% | N/A |
| EPS Growth | ★ 21.05 | N/A |
| EPS | ★ 3.00 | N/A |
| Revenue | $181,464,000.00 | ★ $183,403,000.00 |
| Revenue This Year | $13.13 | $147.34 |
| Revenue Next Year | N/A | $39.11 |
| P/E Ratio | $14.54 | ★ N/A |
| Revenue Growth | 7.63 | ★ 522.13 |
| 52 Week Low | $27.18 | $1.04 |
| 52 Week High | $43.96 | $4.09 |
| Indicator | TRST | GERN |
|---|---|---|
| Relative Strength Index (RSI) | 63.73 | 63.85 |
| Support Level | $41.25 | $1.15 |
| Resistance Level | $43.96 | $1.21 |
| Average True Range (ATR) | 1.08 | 0.05 |
| MACD | 0.15 | 0.02 |
| Stochastic Oscillator | 74.07 | 100.00 |
Trustco Bank Corp N Y is a savings and loan holding company. The core part of a business consists of accepting deposits and making loans and investments. It offers a range of both personal and business banking services. The company's product includes savings accounts; retirement accounts; money market account; mortgages; building loans; auto loans and others. The company based on only one business segment, that of community banking. TrustCo lends in the geographic territory of its branch locations in New York, Florida, Massachusetts, New Jersey, and Vermont.
Geron Corp is a clinical-stage biopharmaceutical company focused on the research and development of cancer treatments. The company's drug in development, Imelstat, is being tested for the treatment of myelodysplastic syndromes, which are disorders of the blood, and myelofibrosis, which is a rare blood cancer affecting bone marrow. The company earns revenue through collaboration agreements, milestones, royalties, and licensing arrangements. Geron possesses various rights to this drug. The company operates as a single segment being, the development of therapeutic products for oncology.